Medicare Drug Price Negotiation Program

The Medicare Drug Price Negotiation Program (MDPNP) is a part of the Inflation Reduction Act (IRA) that sets maximum prices for 10 Medicare Part D-covered drugs for 2026, 15 drugs for 2027, and more drugs (including Part B drugs) beginning in 2028. This program will have significant impacts on pharmacy reimbursement and cash flow models.

Pharmacies are not required by CMS to dispense MDPNP drugs, but individual PBM network agreements may require their dispensing. It is critical that pharmacies read their PBM contracts closely to ensure compliance. For more information, Click Here

Looking for information about the Medicare Prescription Payment Plan (also part of the IRA)? Click Here!
 
 
Check Out the Links Below for More Information
 
MDPNP Basics   MDPNP Selected Drugs & Negotiated Prices

Below are overview resources on the MDPNP program.

  

CMS has provided a list of NDCs that are part of the MDPNP, as well as their negotiated prices.
     
     
     
Manufacturer Agreements   Pharmacy Resources

CMS has provided the list of drug companies that manufacture the selected drugs and will be participating in the MDPNP.

  

Make sure your pharmacy is ready to meet the requirements of the MDPNP, including enrolling in an MTF!